Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | ESR1 | P03372 | 1/20 | 0.33 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.33 |
| ▸ | GABRA1 | P14867 | 3/20 | 0.31 |
| ▸ | GABRB1 | P18505 | 3/20 | 0.31 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29303170 | 0.79 | TRPA1 (0.31) | — | |
| SCHEMBL29303173 | 0.79 | KCNH2 (0.33) | — | |
| SCHEMBL29303187 | 0.75 | CYP1A2 (0.33) | ESR1 | |
| SCHEMBL29303775 | 0.75 | — | — | |
| SCHEMBL20314885 | 0.71 | MAPT (0.41) | CA1CA2ESR1ESR2 | |
| SCHEMBL20314890 | 0.70 | LMNA (0.50) | ESR1ESR2 | |
| SCHEMBL30143439 | 0.70 | ALB (0.38) | CA1CA2ESR1ESR2GABRA1 | |
| SCHEMBL19067389 | 0.69 | NQO2 (0.55) | CA1CA2GABRA1GABRB1GABRB2 | |
| SCHEMBL19170572 | 0.69 | GABRA1 (0.40) | CA1CA2GABRA1GABRB1GABRB2 | |
| SCHEMBL20314903 | 0.69 | CA1 (0.37) | CA1CA2ESR1ESR2GABRA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210009577-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC. | 2021-01-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210009577-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | KRAS, NRAS, HRAS | CA1 2659/4885CA2 2465/4885ESR1 3463/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.